Table 4.

Changes in BMD Measures, Body Composition, Bone Turnover Makers, and Sclerostin in Untreated (AN E−) and Treated (AN E+), Baseline vs. 12 months

	AN E− (n=9)	AN E+(n=13)	p (AN E− vs. AN E +)	p*
Δ CTX (ng/ml)	−0. 075±0. 181	−0. 115±0. 081	NS	NS
Δ P1NP (ng/ml)	−26. 9±61. 8	−8. 4±19. 5	NS	NS
Δ Sclerostin (ng/ml)	−0. 128±0. 042	−0. 101±0. 031	NS	NS
Δ LBMD	0. 005±0. 012	0. 035±0. 007	0. 02	0. 01
Δ % LBMD	−0. 46±1. 5	4. 38±1. 02	0. 02	0. 02
Δ LBMD Z-score	−0. 19±0. 10	0. 21±0. 08	0. 01	0. 01
Δ Weight (kg)	4. 4±1. 3	3. 5±1. 7	NS
Δ BMI (kg/m2)	1. 52±0. 52	1. 10±0. 67	NS
Δ Fat mass (kg)	3. 3±1. 2	1. 6±1. 3	NS
Δ Lean mass (kg)	1. 9±0. 6	0. 8±0. 8	NS

NS: not significant

p*: controlled for baseline age and weight change